• Biotin-16-UTP: Product Overview

  2026-10-08

  Biotin-16-UTP is a biotin-labeled uridine triphosphate analog described for conceptual use in in vitro transcription RNA labeling and related RNA research workflows. No matched paper evidence was provided, so product-specific performance remains unestablished.

• SM-102 and the Freezing-Stress Evidence Gap

  2026-10-08

  SM-102 is best understood as a formulation-dependent component of mRNA delivery rather than an isolated performance variable. This analysis connects its molecular role to new evidence on freezing-induced stress in mRNA-LNPs, clarifying why particle size, encapsulation, and translation can tell different stories.

• pH-Responsive i-Motif ASO Prodrugs in MYCN Cells

  2026-10-07

  Zhang and colleagues developed hairpin antisense oligonucleotide prodrugs that use an i-motif as a pH-responsive structural switch for controlled release. In MYCN-amplified SK-BE(2) cells, selected constructs, particularly R3-5 and R5-5, reduced MYCN expression and promoted apoptosis, although the evidence remains limited to an in vitro model and requires broader validation.

• In Situ CAR-M for HCC: Design and Evidence

  2026-10-07

  Li et al. describe an in situ programmed CAR macrophage that combines GPC3 recognition with IFN-γ signaling and a dominant-negative SIRPα extracellular domain. In preclinical hepatocellular carcinoma models, this architecture increased inflammatory activity, phagocytic function, and tumor-microenvironment reprogramming compared with a CD3ζ-only CAR-M design, while human organoid experiments provided an initial indication of selectivity.

• PXDN, LDHA, and Glycolytic Progression in GBM

  2026-10-06

  Ding and colleagues identify peroxidasin (PXDN) as a glycolysis-associated candidate in glioblastoma and connect it functionally to LDHA, a key regulator of lactate-producing metabolism. The study combines transcriptomic prioritization with cellular and in vivo validation, while its diagnostic and therapeutic implications remain preliminary because independent clinical validation and deeper mechanistic characterization are still needed.

• Cy3 Secondary Antibody and NETs: Five Questions

  2026-10-06

  This source-grounded overview explains how PBDE-47, ROS, Nrf2-associated signaling, NET formation, and fluorescent antibody detection relate to one another. It also separates the reported findings of Ye et al. from what can reasonably be concluded about a Cy3-conjugated secondary antibody, curcumin, human health, and diagnostic use.

• Biotin-16-UTP and Translational RNA Mechanisms

  2026-10-05

  A thought-leadership analysis of how Biotin-16-UTP can support mechanistic investigation of lncRNA–protein interactions, using the reported LINC02870–EIF4G1–SNAIL axis in hepatocellular carcinoma as a translational case study. The article distinguishes reported evidence from future research opportunities and explains how affinity-enabled RNA labeling can strengthen, but not replace, orthogonal validation.

• Nelfinavir Mesylate: Research Context and Evidence

  2026-10-05

  Nelfinavir Mesylate is established as an HIV-1 protease inhibitor and is also being investigated as a chemical probe of the DDI2–NFE2L1 proteostasis pathway in ferroptosis. This overview separates supplier-reported antiviral properties from findings in a 2025 Cell Death & Differentiation study, compares the strength of the evidence, and outlines conceptual applications and translational limitations without presenting experimental procedures.

• Cy3 Anti-Rabbit IgG in DSS Colitis Research

  2026-10-04

  A source-grounded overview of how Cy3 fluorescence can support spatial protein analysis in ulcerative-colitis research, alongside the reported findings and limitations of a 2025 XAV939 study in DSS-induced colitis.

• Elobixibat and Bile Acid Signaling in Constipation

  2026-10-03

  The 2014 review by Acosta and Camilleri presents elobixibat as an ileal bile acid transporter inhibitor that targets enterohepatic bile acid circulation rather than acting only through conventional laxative mechanisms. Its main contribution is a physiological framework linking reduced ileal bile acid reabsorption with greater colonic bile acid exposure, secretion, and motility, while also emphasizing that early evidence did not yet establish comparative superiority or long-term clinical outcomes.

• Eltanexor: A Pathway-Aware XPO1 Assay Strategy

  2026-10-02

  Eltanexor (KPT-8602) is an oral bioavailable XPO1 inhibitor with applications spanning leukemia, lymphoma, and colorectal cancer research. This guide translates recent Wnt/β-catenin findings into a pathway-aware strategy for selecting models, controls, and readouts.

• PD 0332991: CDK4/6 Workflows for Rb-Positive Models

  2026-10-01

  Build a mechanism-first workflow around PD 0332991 to connect CDK4/6 inhibition with Rb phosphorylation, G1 arrest, and growth control. Genomic pre-screening, time-resolved cell-cycle analysis, and cytostasis-versus-death measurements make the compound especially useful for comparing breast cancer, hematologic, and hypothesis-generating mesothelioma models.

• Ruthenium Red in Force-Responsive Autophagy

  2026-10-01

  Ruthenium Red provides a practical Ca2+ transport inhibitor strategy for testing whether calcium flux links mechanical stress to autophagy. This article integrates product pharmacology with recent cytoskeleton-dependent compression research to guide causal, better-controlled assay design.

• From Transfection to Translational Control

  2026-09-30

  How delivery quality shapes nucleic acid biology, using pH-responsive antisense design and Lipo3K Transfection Reagent to connect mechanistic insight with reproducible translational workflows.

• From Delivery to Mechanism in ccRCC Resistance

  2026-09-30

  A translational framework for using Lipo3K Transfection Reagent to test OTUD3–SLC7A11 ferroptosis biology, strengthen causal evidence, and advance sunitinib-resistance studies in challenging renal cancer models.

8106 records 1/541 page Next 12345 下5页 Last page